PAST EVENT: Rocky Mountain Life Sciences Investor and Partnering Conference

Medecipher has been selected as one of the first round companies to present at the Colorado Bioscience Association’s Rocky Mountain Life Sciences Investor + Partnering Conference in September 2022. The event takes place on September 13th and 14th in Vail, Colorado.

The conference was developed as a vehicle for selected life science startup companies to showcase their ideas to medical investors and potential partners across the U.S. Since the last conference, held in 2019, the Colorado Bioscience Association has continued to be a leader in breakthrough research and commercialization.

We are excited and grateful for this opportunity to present at the Rocky Mountain Life Sciences Investor & Partnering Conference and share our nurse-centric decision support platform addressing the #1 issue facing healthcare leaders today, nurse staffing, with investors and strategic partners from across the U.S.”

Stephanie Gravenor, CEO

Medecipher will present FLO, a cloud-based solution that supports annual, monthly, and daily nurse staffing decisions and incorporates each hospital’s unique constraints: position control, budget, nursing preference, and ease-of-use. FLO is proven to reduce staff churn, improve operations, maintain safer staffing levels, and improve staff and provider satisfaction.

Join Medecipher in Vail on September 13th and 14th to learn more.

About Colorado Bioscience Association 

The Colorado Bioscience Association team advances life sciences in Colorado by building a collaborative, pro-innovation business environment. The Association expands access to capital, offers education and networking opportunities for their members, advocates for life sciences in Colorado by creating strong partnerships with policymakers and business leaders, connects their members to job seekers and job opportunities, and cultivates an educated, experienced workforce with skill development and leadership training through their Colorado BioScience Institute.